ESR1 and breast carcinoma: To assess the functional role of MaTAR25, we proceeded to genetically KO MaTAR25 in highly aggressive 4T1 triple-negative (ER−, PR−, HER2−) mammary carcinoma cells using CRISPR/Cas9.